Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 21, 2020

View Archived Issues

Another obstacle to universal flu vaccine

ORIC Pharmaceuticals' OP-4954 displays selective glucocorticoid receptor antagonism

Promising preclinical data for novel lymph node targeting COVID-19 vaccine

Phosphodiesterase PDE3A and PDE3B inhibitors described by Bayer, The Broad Institute

Jiangsu Hengrui Medicine, Shanghai Hengrui Pharmaceutical patent ADORA2A/B antagonists

Jiangsu Chia Tai Tianqing Pharmaceutical discovers HBV capsid assembly inhibitors

New opioid receptor ligands identified at Yangtze River Pharmaceutical

Esteve presents dual sigma1 and mu-opioid receptor ligands

Genmab initiates first-in-human study of GEN-1044

Takeda starts enrollment in first-in-human trial of TAK-102

Enrollment ongoing in phase I/II study of TAEK-VAC-HerBy vaccine

First participant vaccinated in phase III study of MenABCWY meningitis vaccine candidate

Tankyrase inhibition with OM-153 shows potential for immuno-oncology

Ascletis completed bridging study of ASC-18 FDC pill for the treatment of hepatitis C

Repurposing of low-cost generic nafamostat as COVID-19 therapy

First healthy volunteer dosed in phase I clinical program of IMU-856

Positive early data for lead mRNA COVID-19 vaccine candidate BNT-162b2

Orally active STING agonists stimulate innate immunity

FDA approves Kesimpta for the treatment of relapsing multiple sclerosis

Imfinzi receives Japanese approval for the treatment of extensive-stage SCLC

First-in-human proof-of-concept trial for HBV treatment ALG-010133 begins

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 12, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 9, 2026
Skape Bio unlocks GPCR targets with de novo-designed miniproteins
BioWorld
Modulating G protein-coupled receptors (GPCRs) is one of the major challenges in biomedicine. These are flexible proteins with small, deep binding pockets. The...
Pre-disease plasma signature may help redefine lung cancer risk
BioWorld
Researchers have identified a 14-protein blood signature that can predict lung cancer risk as much as five years before diagnosis, and the findings could help...
New 5-HT2C receptor agonists reported in Hansoh patent
BioWorld Science
Researchers from Jiangsu Hansoh Pharmaceutical Group Co. Ltd. and Shanghai Hansoh Biomedical Co. Ltd. have disclosed tricyclic compounds acting as 5-HT2C receptor...